Gene testing identifies lung cancer patients who benefit from ALK-inhibitor drug

Results of a new study in non-small cell lung cancer showed that patients with specific oncogenic rearrangements of the anaplastic lymphoma kinase (ALK) gene within the short arm of chromosome 2 of their tumors had a much greater response to a new therapy - an ALK-inhibitor.

Read the whole article on Physorg

More from Physorg